Patient-Focused Medicines Development: Where It has Led us to Today, What Challenges Remain, and What Do we Still Need to do to Achieve Success?
Veronica L. Todaro, MPH
Vice President, National Programs
Parkinson's Foundation, United States
Using a multi-disciplinary approach, we will take a dynamic look at the experience of those involved in patient engagement, across stakeholder groups representing different regions, to understand
how we have collectively moved the needle. As organizations have embarked upon efforts and implemented initiatives, we will provide a bird’s eye view of the impact of patient engagement across various stakeholders.
Learning Objective : Describe how patient engagement has evolved across stakeholder groups in the past few years
Discuss the impact of collective approaches on patient engagement in medicines development lifecycle
Apply key learnings from collective approaches in their own efforts
Describe recent achievements in patient engagement and identify remaining challenges
What Remains to be Done to Deliver Patient-Focused Medicines: Where Do We Go From Here? How Can We collaboratively Build on What We Know
Sarah Krug, MS, MSc
CANCER101, United States